November 8th, 2022 Taipei, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and development partner, AimMax Therapeutics, Inc. (US), announced the completion of a pre-NDA meeting with the US FDA for its lead program, APP13007, a 14-day, twice-daily eyedrop for the treatment of inflammation and pain after ocular surgery. The favorable outcome of the meeting lays the …
TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-302, the second of the two pivotal Phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain after cataract surgery. CPN-302 was …
TAIPEI, May 12, 2022 /PRNewswire/ — Formosa Pharmaceuticals, Inc. (TWO.6838) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-301, the first of two pivotal Phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of a potent corticosteroid, clobetasol propionate(0.05%), for the treatment of inflammation and pain after cataract surgery. CPN-301 …
TAIPEI, Taiwan, March 24, 2022 – Formosa Pharmaceuticals, Inc. (6838.TWO) announce the approval of a resolution by the boards of directors of both Formosa Pharmaceuticals and EirGenix, Inc. (6589.TT) for the co-development of anticancer ADC, TSY-0110 (EG12043). This agreement strengthens the existing relationship between both companies and fortifies TSY-0110’s clinical development pathway and subsequent licensing …
TAIPEI – October 5, 2021 – Formosa Pharmaceuticals (“Formosa”, stock code: 6838) announce its registration on the Emerging Stock Board of the Taipei Stock Exchange (TPEx) as of October 7. The listing price is NT $32 per share (approx. USD $1.15). Formosa Pharmaceuticals (6838) was established in 2010 and has a paid-in capital of NT …